Exhibit 99.1 ALAMEDA, Calif., July 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2024. • U.S. thrombectomy revenue of $153.7 million in the second quarter of 2024 increased 24.9% compared to the second quarter of 2023. • Adjusted EBITDA of $46.3 million or adjusted EBITDA margin of 15.5% in the second quarter of 2024. 1 Second Quarter 2024 Financial Results Gross profit ...

U.S. thrombectomy revenue of $153.7 million in the second quarter of 2024 increased 24.9% compared to the second quarter of 2023. Cash and marketable investments increased $26.2 million in the second quarter of 2024 compared to the first quarter of 2024 driven by an increase in non-GAAP profitability and improvements in working capital. Updated Full Year 2024 Financial Outlook 1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. Constant Currency. The Company's co ...

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. Value Score Momentum Score If you like to use all three kinds of investing, ...

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30. On the other hand, if they miss, the stock may move lower. Zacks Consensus Estimate Revenues are expected to be $298.58 million, up 14.2% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.48% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reasses ...

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform. It does ...

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Penumbra (PEN) shares ended the last trading session 3.3% higher at $203.22. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.8% gain over the past four weeks. This medical device maker is expected to post quarterly earnings of $0.56 per share in its upcoming report, which repres ...

There have been upward revisions in current-year earnings estimates for Penumbra. The Zacks Consensus Estimate for the current year has surged 0.4% over the past month. While the overall earnings estimate revisions have made Penumbra a Zacks Rank #2 stock, it has earned itself a Growth Score of A based on a number of factors, including the ones discussed above. This combination positions Penumbra well for outperformance, so growth investors may want to bet on it. Growth stocks are attractive to many investo ...

The average comprises 13 short-term price targets ranging from a low of $210 to a high of $289, with a standard deviation of $24.61. While the lowest estimate indicates an increase of 6.7% from the current price level, the most optimistic estimate points to a 46.9% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. But, for PEN, an impressive average p ...

Investor Relations Penumbra, Inc. [email protected] Source: Penumbra, Inc. Webcast & Conference Call Information Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more in ...

Toronto, Ontario--(Newsfile Corp. - July 2, 2024) - Peninsula Energy (ASX: PEN) is pleased to announce that the company is presenting a live virtual corporate update hosted by Red Cloud Financial Services on July 9th, 2024 at 2:00pm ET. About Peninsula Energy Peninsula Energy Wayne Heili +61893809920 info@pel.net.au The replay will be emailed out to all webinar registrants proceeding the event and will also be available on the Red Cloud website. About Red Cloud Financial Services Inc. www.redcloudfs.com www ...